Medicare Advantage premiums expected to drop more than 16% in 2027, CMS projects

CMS projects the weighted average Medicare Advantage monthly premium will fall more than 16% to $12 in 2027 from $14.37 in 2026, while MA prescription-drug premiums are expected to decline 38%. Insurers are reducing exposure to less-profitable markets as rising costs pressure margins: Barclays estimates Humana's 3,995 gross plan exits affect 942,000 members, or 19% of its retail MA membership. MA enrollment is projected at 34 million, or 47.4% of Medicare beneficiaries, though CMS expects eventual enrollment to exceed that estimate.

Analysis

The relevant signal is not the lower headline premium but the industry’s willingness to trade enrollment for underwriting discipline. HUM’s outsized footprint reduction creates the largest near-term membership-disruption pool; ELV, with a relatively stable geographic offering, is best positioned to capture profitable switchers without matching uneconomic benefits. UNH can selectively absorb membership but has less need to do so given its broader Optum earnings base, while CVS faces the least attractive setup because MA retention pressure coincides with a still-repairing Aetna margin profile.

For the October-December enrollment period, plan exits should improve sector pricing behavior and reduce the probability of another broad 2027 benefit-rich competitive cycle. The 1-3 month catalyst is county-level plan mapping and early broker/channel commentary: net enrollment gains in exited HUM counties would validate ELV as the share-take beneficiary, whereas widespread beneficiary migration to low-premium UNH/CVS products would pressure industry margins. The key falsifier is a negative 2027 MA rate or risk-adjustment policy surprise; absent adequate CMS funding, enrollment growth is value-destructive even for apparent share winners.

Consensus may over-penalize HUM for gross exits while underappreciating the medical-cost and administrative leverage from shedding marginal counties. HUM is a higher-beta margin-recovery vehicle over 6-18 months, but it remains dependent on proving that its remaining book can meet target margins. ELV offers the cleaner relative long because selective share capture can support growth without requiring a major turnaround, while UNH’s valuation is likely more sensitive to regulatory and reimbursement scrutiny than to incremental MA enrollment.

Key Decisions for Investors

• Initiate a 3-6 month long ELV / short CVS pair, sized dollar-neutral: ELV has the clearest opportunity to acquire displaced members while CVS remains exposed to retention spending and Aetna margin repair. Reassess if early enrollment data indicate ELV is not gaining share in counties with major HUM exits.
• Maintain HUM as a tactical watch-to-buy rather than chase immediately; enter following evidence of favorable enrollment mix or reaffirmed 2027 margin targets. Upside is multiple re-rating on credible margin recovery, but exit if management signals further material footprint reductions or reduced per-member profitability guidance.
• Underweight CVS into enrollment read-throughs and 2027 reimbursement visibility. Cover the short if Aetna reports materially better medical-cost trends or management demonstrates that plan rationalization is lifting MA margins faster than expected.
• Use the CMS final 2027 MA rate/risk-adjustment framework as the sector risk trigger: a funding outcome below insurer assumptions would invalidate long exposure to MA-heavy carriers; a constructive rate outcome favors HUM most on operating leverage and ELV second on profitable share capture.